const L117L118 = [
{
"id": 1,
"category": "Adverse Drug Reactions: Type A",
"questionText": "A 70-year-old patient with congestive heart failure is maintained on a daily dose of digoxin. His renal function, which was previously normal, begins to decline. He develops nausea, vomiting, and visual disturbances (yellow-green halos). This patient's presentation is best classified as which type of adverse drug reaction?",
"options": [
{"text": "Type A (Augmented)", "explanation": "Correct. This is a predictable, dose-dependent toxic effect of digoxin, which has a narrow therapeutic index and is renally cleared. The declining renal function led to drug accumulation and toxicity."},
{"text": "Type B (Bizarre/Idiosyncratic)", "explanation": "This is incorrect. Digoxin toxicity is a well-known, predictable, and dose-dependent reaction, not an unpredictable idiosyncratic or immunologic reaction."},
{"text": "Type C (Chronic)", "explanation": "This is incorrect. Type C reactions are related to long-term cumulative dose and time, such as tolerance or dependence, not acute toxicity from reduced clearance."},
{"text": "Type D (Delayed)", "explanation": "This is incorrect. Type D reactions, like carcinogenesis, occur a long time after exposure and are not related to this acute presentation."},
{"text": "Type F (Failure)", "explanation": "This is incorrect. Type F is a failure of therapy (e.g., from a drug interaction), not a toxic effect from drug accumulation."}
],
"correctAnswerIndex": 0,
"slideImagePath": "images/L117L118_p_page-0011.jpg"
},
{
"id": 2,
"category": "Adverse Drug Reactions: Type B (Hypersensitivity)",
"questionText": "A 22-year-old male is given penicillin for a streptococcal infection. Within minutes, he develops urticaria, severe dyspnea, and hypotension. This IgE-mediated reaction, which is not dose-dependent and is unpredictable, is classified as which type of adverse drug reaction?",
"options": [
{"text": "Type A (Augmented)", "explanation": "This is incorrect. Type A reactions are dose-dependent and predictable, whereas anaphylaxis is an unpredictable (idiosyncratic) immunologic reaction."},
{"text": "Type B (Bizarre/Idiosyncratic)", "explanation": "Correct. This is a Type B (Bizarre) reaction, specifically a Type I (anaphylactic) hypersensitivity, which is immunologic, not dose-dependent, and unpredictable in a non-sensitized patient."},
{"text": "Type C (Chronic)", "explanation": "This is incorrect. This is an acute, immediate reaction, not one related to chronic, cumulative dosing."},
{"text": "Type D (Delayed)", "explanation": "This is incorrect. While some Type D reactions (like SJS) are delayed, this patient's immediate anaphylactic reaction is not a Type D (delayed) effect like teratogenesis."},
{"text": "Type E (End of Use)", "explanation": "This is incorrect. Type E reactions are due to withdrawal or stopping a drug, not an acute reaction to its administration."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0027.jpg"
},
{
"id": 3,
"category": "Pharmacogenomics: CYP2D6",
"questionText": "A 30-year-old woman is given codeine for post-surgical pain. She experiences severe respiratory depression and sedation, requiring naloxone. The patient is most likely an 'ultra-rapid metabolizer' due to a polymorphism in which enzyme, which converts the prodrug codeine to its active metabolite, morphine?",
"options": [
{"text": "CYP2C19", "explanation": "This enzyme is responsible for activating the prodrug clopidogrel; its role in codeine metabolism is minor."},
{"text": "CYP2C9", "explanation": "This enzyme is primarily responsible for metabolizing warfarin."},
{"text": "CYP2D6", "explanation": "Correct. CYP2D6 is the enzyme that converts the prodrug codeine into its highly active metabolite, morphine. Ultra-rapid metabolizers (e.g., via gene duplication) produce dangerously high levels of morphine, leading to toxicity."},
{"text": "TPMT", "explanation": "This enzyme is responsible for metabolizing azathioprine; low activity leads to myelosuppression."},
{"text": "G6PD", "explanation": "This is an enzyme in the RBC hexose monophosphate shunt; deficiency leads to hemolytic anemia with oxidative drugs."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0034.jpg"
},
{
"id": 4,
"category": "Pharmacogenomics: CYP2C19",
"questionText": "A 55-year-old man undergoes coronary stenting and is placed on dual anti-platelet therapy, including clopidogrel. Two weeks later, he presents with an acute in-stent thrombosis. Genetic testing reveals he is a 'poor metabolizer' due to a loss-of-function allele. This therapeutic failure is due to an inability to activate the prodrug via which enzyme?",
"options": [
{"text": "CYP2D6", "explanation": "This enzyme is primarily responsible for activating the prodrug codeine."},
{"text": "CYP2C19", "explanation": "Correct. Clopidogrel is a prodrug that requires activation by CYP2C19. Poor metabolizers cannot generate sufficient active metabolite, leading to therapeutic failure and high risk of stent thrombosis."},
{"text": "CYP3A4", "explanation": "While CYP3A4 is involved in many drug interactions, CYP2C19 is the key enzyme for clopidogrel activation."},
{"text": "VKORC1", "explanation": "This is the molecular target of warfarin, not an enzyme for clopidogrel activation."},
{"text": "SLCO1B1", "explanation": "This is a hepatic uptake transporter; variants are associated with simvastatin-induced myopathy."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0033.jpg"
},
{
"id": 5,
"category": "Pharmacogenomics: CYP2D6",
"questionText": "A 28-year-old female is prescribed codeine for a severe cough. After 3 days, she reports no relief from her cough and no other effects. The patient is most likely a 'poor metabolizer' due to a lack of function in which enzyme?",
"options": [
{"text": "CYP2D6", "explanation": "Correct. Codeine is a prodrug that must be metabolized by CYP2D6 to morphine (which provides analgesia and antitussive effects). A poor metabolizer cannot perform this conversion, resulting in therapeutic failure."},
{"text": "CYP2C19", "explanation": "This enzyme is primarily responsible for activating clopidogrel, not codeine."},
{"text": "NUDT15", "explanation": "This enzyme, along with TPMT, is involved in metabolizing azathioprine."},
{"text": "CYP2C9", "explanation": "This enzyme is primarily responsible for metabolizing warfarin."},
{"text": "G6PD", "explanation": "Deficiency in this enzyme is associated with hemolytic anemia, not a lack of codeine efficacy."}
],
"correctAnswerIndex": 0,
"slideImagePath": "images/L117L118_p_page-0034.jpg"
},
{
"id": 6,
"category": "Pharmacogenomics: TPMT",
"questionText": "A 19-year-old male with Crohn's disease is started on azathioprine. Genetic screening prior to treatment indicates he is homozygous for a loss-of-function variant in TPMT. If given a standard dose, this patient is at an extremely high risk for which adverse drug reaction?",
"options": [
{"text": "Hepatotoxicity", "explanation": "While azathioprine can be hepatotoxic, the most severe, life-threatening risk in TPMT deficiency is myelosuppression."},
{"text": "Severe myelosuppression", "explanation": "Correct. Azathioprine is metabolized by TPMT. Patients with low/absent TPMT activity cannot break down the active metabolites (6-thioguanine nucleotides), leading to their massive accumulation and life-threatening bone marrow suppression (myelosuppression)."},
{"text": "Anaphylaxis (Type I hypersensitivity)", "explanation": "This is an IgE-mediated reaction and is not the mechanism for TPMT-related toxicity."},
{"text": "Hemolytic anemia", "explanation": "This is characteristic of G6PD deficiency when exposed to oxidative drugs, not TPMT deficiency."},
{"text": "Stevens-Johnson Syndrome (SJS)", "explanation": "This Type IV hypersensitivity is associated with drugs like carbamazepine in HLA-B*15:02 positive patients."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0033.jpg"
},
{
"id": 7,
"category": "Pharmacogenomics: G6PD Deficiency",
"questionText": "An African American male is being treated for a urinary tract infection with nitrofurantoin. Several days later, he presents with fatigue, jaundice, and dark urine. Lab work confirms acute hemolytic anemia. This idiosyncratic (Type B) reaction is most likely due to an X-linked deficiency in which enzyme?",
"options": [
{"text": "CYP2C9", "explanation": "This enzyme metabolizes warfarin; it is not associated with drug-induced hemolytic anemia."},
{"text": "TPMT", "explanation": "Deficiency in this enzyme leads to myelosuppression with azathioprine, not hemolytic anemia."},
{"text": "HLA-B*57:01", "explanation": "This is an HLA allele, not an enzyme. It is associated with abacavir hypersensitivity."},
{"text": "G6PD (Glucose-6-Phosphate Dehydrogenase)", "explanation": "Correct. G6PD deficiency is an X-linked condition (common in African, Asian, and Mediterranean populations) that makes RBCs vulnerable to oxidative stress from drugs like nitrofurantoin, sulfonamides, and antimalarials, leading to hemolytic anemia."},
{"text": "SLCO1B1", "explanation": "This is a transporter polymorphism associated with statin-induced myopathy, not hemolytic anemia."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0037.jpg"
},
{
"id": 8,
"category": "Pharmacogenomics: HLA Alleles",
"questionText": "A 30-year-old man of Han Chinese descent is diagnosed with trigeminal neuralgia. The physician plans to start treatment with carbamazepine but first orders a genetic test. The physician is screening for the HLA-B*15:02 allele to prevent which severe adverse drug reaction?",
"options": [
{"text": "Hepatotoxicity", "explanation": "While carbamazepine can be hepatotoxic, the specific, life-threatening reaction associated with HLA-B*15:02 is SJS/TEN."},
{"text": "Agranulocytosis", "explanation": "Agranulocytosis is a known risk of carbamazepine, but it is not specifically linked to the HLA-B*15:02 allele."},
{"text": "Fatal hypersensitivity syndrome", "explanation": "This systemic reaction is more characteristic of the HLA-B*57:01 allele with abacavir."},
{"text": "Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN)", "explanation": "Correct. The HLA-B*15:02 allele, found almost exclusively in patients of Asian ancestry, is strongly associated with a risk of developing SJS/TEN (a severe Type IV hypersensitivity) when exposed to carbamazepine."},
{"text": "Drug-induced lupus erythematosus", "explanation": "This reaction is more commonly associated with drugs like hydralazine or procainamide."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0040.jpg"
},
{
"id": 9,
"category": "Pharmacogenomics: HLA Alleles",
"questionText": "A 45-year-old male is diagnosed with HIV. Before initiating antiretroviral therapy that includes abacavir, his physician orders an HLA-B test. The test comes back positive for the *57:01 allele. Starting abacavir in this patient would put him at high risk for what outcome?",
"options": [
{"text": "Therapeutic failure due to ultra-rapid metabolism.", "explanation": "This describes a pharmacokinetic interaction (e.g., CYP2D6/codeine), not the pharmacodynamic hypersensitivity associated with HLA-B*57:01."},
{"text": "A severe, potentially fatal multi-organ hypersensitivity reaction.", "explanation": "Correct. The presence of the HLA-B*57:01 allele confers a high risk of a severe, multi-organ hypersensitivity reaction to abacavir. Screening is mandatory, and the drug is contraindicated in positive patients."},
{"text": "Stevens-Johnson Syndrome (SJS).", "explanation": "SJS is associated with the HLA-B*15:02 allele and carbamazepine, not HLA-B*57:01 and abacavir."},
{"text": "Acute hemolytic anemia.", "explanation": "This is associated with G6PD deficiency and oxidative drugs."},
{"text": "Statin-induced myopathy.", "explanation": "This is associated with SLCO1B1 polymorphisms."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0041.jpg"
},
{
"id": 10,
"category": "Pharmacogenomics: SLCO1B1",
"questionText": "A 60-year-old patient taking simvastatin 40 mg daily complains of severe muscle pain and weakness. Lab work reveals a highly elevated creatine kinase (CK) level, consistent with rhabdomyolysis. This patient's adverse reaction is most likely due to a polymorphism in a gene that codes for what type of protein?",
"options": [
{"text": "A drug-metabolizing enzyme (CYP450)", "explanation": "While CYP3A4 is involved in statin metabolism, the specific genetic variant strongly linked to myopathy is in a *transporter* gene, not a CYP gene."},
{"text": "A drug transporter protein (SLCO1B1)", "explanation": "Correct. The SLCO1B1 gene codes for the OATP1B1 transporter, which is responsible for the hepatic uptake of statins. A loss-of-function variant reduces this uptake, leading to much higher plasma concentrations and increased risk of myopathy."},
{"text": "An HLA allele (HLA-B)", "explanation": "HLA alleles are associated with hypersensitivity reactions (e.g., abacavir, carbamazepine), not statin myopathy."},
{"text": "An X-linked enzyme (G6PD)", "explanation": "G6PD deficiency is associated with hemolytic anemia, not myopathy."},
{"text": "A drug target (VKORC1)", "explanation": "VKORC1 is the target for warfarin; the target for statins is HMG-CoA reductase."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0031.jpg"
},
{
"id": 11,
"category": "Drug Toxicity: Acetaminophen",
"questionText": "A 19-year-old college student is brought to the ED after ingesting an entire bottle of acetaminophen in a suicide attempt. This overdose is life-threatening because the toxic metabolite, NAPQI, causes severe hepatotoxicity by what mechanism?",
"options": [
{"text": "Inhibiting CYP2E1 enzymes, leading to liver failure.", "explanation": "CYP2E1 is one of the enzymes that *creates* the toxic metabolite NAPQI, it is not inhibited by it."},
{"text": "Depleting hepatic glutathione stores, leading to oxidative damage.", "explanation": "Correct. At therapeutic doses, NAPQI is safely detoxified by conjugation with glutathione. In an overdose, glutathione stores are depleted, allowing NAPQI to cause massive oxidative damage and hepatocellular necrosis."},
{"text": "Causing metabolic acidosis and uncoupling oxidative phosphorylation.", "explanation": "This is the mechanism of toxicity for *salicylates (aspirin)*, not acetaminophen."},
{"text": "Binding to mu-opioid receptors, causing respiratory depression.", "explanation": "This is the mechanism of toxicity for *opioids*, not acetaminophen."},
{"text": "Irreversibly inhibiting acetylcholinesterase.", "explanation": "This is the mechanism of toxicity for *organophosphates*, not acetaminophen."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0014.jpg"
},
{
"id": 12,
"category": "Drug Toxicity: Antidotes (Acetaminophen)",
"questionText": "A patient is admitted to the hospital for a severe acetaminophen overdose. To prevent lethal hepatotoxicity, the physician administers N-acetylcysteine (NAC). What is the mechanism of action for this antidote?",
"options": [
{"text": "It acts as a competitive antagonist at the opioid receptor.", "explanation": "This is the mechanism of *naloxone* for opioid overdose."},
{"text": "It alkalinizes the urine to promote renal excretion of the drug.", "explanation": "This is the treatment for *salicylate* overdose."},
{"text": "It regenerates acetylcholinesterase that has been inhibited.", "explanation": "This is the mechanism of *pralidoxime (2-PAM)* for organophosphate poisoning."},
{"text": "It acts as a glutathione precursor, replenishing hepatic stores.", "explanation": "Correct. N-acetylcysteine (NAC) acts as a precursor for glutathione, replenishing the hepatic stores needed to detoxify the toxic metabolite NAPQI."},
{"text": "It is a benzodiazepine used to manage CNS agitation and seizures.", "explanation": "This describes the treatment for *cocaine* toxicity."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0014.jpg"
},
{
"id": 13,
"category": "Drug Toxicity: Salicylates",
"questionText": "A 24-year-old patient presents to the ED with confusion, ringing in the ears (tinnitus), a high fever, and rapid breathing. An arterial blood gas reveals a mixed primary respiratory alkalosis and primary metabolic acidosis. This presentation is classic for an overdose of which substance?",
"options": [
{"text": "Acetaminophen", "explanation": "Acetaminophen overdose primarily causes hepatotoxicity; it does not cause this classic mixed acid-base disorder."},
{"text": "Opioids (e.g., Fentanyl)", "explanation": "Opioid overdose causes respiratory depression (acidosis) and miosis, not respiratory alkalosis and tinnitus."},
{"text": "Cocaine", "explanation": "Cocaine toxicity presents with sympathomimetic signs (tachycardia, hypertension, mydriasis), not this acid-base disorder."},
{"text": "Organophosphates", "explanation": "Organophosphate poisoning causes a cholinergic crisis (DUMBBELSS), not this acid-base disorder."},
{"text": "Salicylates (Aspirin)", "explanation": "Correct. Salicylate overdose classically presents with tinnitus and a mixed acid-base disorder: direct respiratory center stimulation causes respiratory alkalosis, while uncoupling of oxidative phosphorylation causes metabolic acidosis."}
],
"correctAnswerIndex": 4,
"slideImagePath": "images/L117L118_p_page-0003.jpg"
},
{
"id": 14,
"category": "Drug Toxicity: Antidotes (Salicylates)",
"questionText": "A patient with a severe salicylate (aspirin) overdose and metabolic acidosis is treated with an IV infusion of sodium bicarbonate. What is the primary pharmacokinetic goal of this antidote?",
"options": [
{"text": "To replenish hepatic glutathione stores.", "explanation": "This is the mechanism of *N-acetylcysteine* for acetaminophen overdose."},
{"text": "To competitively antagonize the drug at its receptor.", "explanation": "This is a pharmacodynamic antagonism (like naloxone); sodium bicarbonate works via a pharmacokinetic mechanism."},
{"text": "To alkalinize the urine and promote renal excretion.", "explanation": "Correct. Salicylate is a weak acid. Alkalinizing the urine (pH trapping) ionizes the drug, preventing its reabsorption in the renal tubules and dramatically increasing its excretion."},
{"text": "To reactivate inhibited acetylcholinesterase.", "explanation": "This is the mechanism of *pralidoxime (2-PAM)* for organophosphate poisoning."},
{"text": "To bind the drug in the GI tract (chelation).", "explanation": "This describes activated charcoal, which would be given much earlier; sodium bicarbonate works on *systemic* elimination."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0003.jpg"
},
{
"id": 15,
"category": "Drug Toxicity: Opioids",
"questionText": "A 25-year-old male is found unresponsive. His friends state he was 'using heroin.' On physical exam, he has a respiratory rate of 4 breaths/minute, cyanosis, and pinpoint pupils (miosis). This classic triad of toxicity is best treated with which antidote?",
"options": [
{"text": "N-acetylcysteine (NAC)", "explanation": "This is the antidote for acetaminophen overdose."},
{"text": "Benzodiazepines", "explanation": "This is the treatment for CNS agitation/seizures, such as in cocaine overdose, not respiratory depression."},
{"text": "Pralidoxime (2-PAM)", "explanation": "This is an antidote for organophosphate poisoning."},
{"text": "Naloxone", "explanation": "Correct. Naloxone is a competitive antagonist at the mu-opioid receptor and is the first-line antidote for reversing the life-threatening respiratory depression and miosis of an opioid overdose."},
{"text": "Sodium bicarbonate", "explanation": "This is the treatment for salicylate overdose."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 16,
"category": "Drug Toxicity: Cocaine",
"questionText": "A 30-year-old male is brought to the ED from a party, exhibiting extreme agitation, paranoia, tachycardia, hypertension (210/120 mmHg), and mydriasis (dilated pupils). He is at high risk for myocardial infarction due to vasospasm. What is the most appropriate *initial* treatment for his agitation and seizures?",
"options": [
{"text": "Propranolol (a beta-blocker)", "explanation": "Beta-blockers are contraindicated in cocaine toxicity, as they can lead to *unopposed* alpha-adrenergic stimulation, worsening hypertension and vasospasm."},
{"text": "Naloxone", "explanation": "Naloxone is the antidote for opioid overdose, which presents with *opposite* symptoms (respiratory depression, miosis)."},
{"text": "Benzodiazepines (e.g., lorazepam)", "explanation": "Correct. Benzodiazepines are the first-line treatment for cocaine toxicity to control CNS agitation, seizures, and sympathomimetic effects (tachycardia, hypertension)."},
{"text": "N-acetylcysteine (NAC)", "explanation": "This is the antidote for acetaminophen overdose."},
{"text": "Atropine", "explanation": "Atropine is an anticholinergic used for *bradycardia* or organophosphate poisoning; this patient is tachycardic."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0003.jpg"
},
{
"id": 17,
"category": "Drug Toxicity: Organophosphates",
"questionText": "A 50-year-old farmer is brought to the ED after a pesticide spill. He is experiencing profuse salivation, lacrimation, urination, defecation, GI distress, and emesis (DUMBBELSS). He also has muscle weakness and bradycardia. This cholinergic crisis requires which two antidotes?",
"options": [
{"text": "Naloxone and Sodium Bicarbonate", "explanation": "These are antidotes for opioid and salicylate overdoses, respectively."},
{"text": "Benzodiazepines and Phentolamine", "explanation": "These are treatments for cocaine toxicity."},
{"text": "N-acetylcysteine and Fomepizole", "explanation": "NAC is for acetaminophen overdose; fomepizole is for ethylene glycol/methanol poisoning."},
{"text": "Atropine and Pralidoxime (2-PAM)", "explanation": "Correct. Atropine is a muscarinic antagonist that dries up secretions (reversing DUMBBELSS), while 2-PAM reactivates the acetylcholinesterase enzyme that was irreversibly inhibited by the organophosphate."},
{"text": "Propranolol and Atropine", "explanation": "Propranolol (a beta-blocker) is not indicated; 2-PAM is needed to reactivate the enzyme and treat the nicotinic (muscle weakness) symptoms."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 18,
"category": "Adverse Drug Reactions: Type C/E",
"questionText": "A patient has been taking high-dose benzodiazepines daily for 3 years for anxiety. He abruptly stops the medication. Two days later, he develops severe anxiety, insomnia, tremors, and a seizure. This presentation is best classified as which type of adverse drug reaction?",
"options": [
{"text": "Type A (Augmented)", "explanation": "This is incorrect. Type A reactions are a direct pharmacologic effect of the drug, not a syndrome caused by its absence."},
{"text": "Type B (Bizarre/Idiosyncratic)", "explanation": "This is incorrect. Withdrawal is a predictable, dose- and time-dependent phenomenon in a physically dependent person, not an unpredictable idiosyncratic reaction."},
{"text": "Type D (Delayed)", "explanation": "This is incorrect. This is an immediate consequence of stopping the drug, not a delayed effect like carcinogenesis."},
{"text": "Type E (End of Use / Withdrawal)", "explanation": "Correct. This is a classic Type E (End of Use) reaction, also known as a withdrawal syndrome, which occurs when a drug causing physical dependence (Type C) is stopped abruptly."},
{"text": "Type F (Failure)", "explanation": "This is incorrect. This is a reaction to the *absence* of the drug, not a *failure* of the drug to work."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0012.jpg"
},
{
"id": 19,
"category": "Adverse Drug Reactions: Teratogenicity",
"questionText": "A 30-year-old pregnant woman in her first trimester is found to be taking a medication for hypertension that is contraindicated in pregnancy. This drug is known to cause fetal renal damage, oligohydramnios, and skull hypoplasia. Which class of medication is this teratogen?",
"options": [
{"text": "Beta-blockers (e.g., Labetalol)", "explanation": "Labetalol is commonly used to *treat* hypertension in pregnancy; it is not a major teratogen."},
{"text": "Thalidomide", "explanation": "Thalidomide is a potent teratogen known for causing phocomelia (limb deformities), but it is not an antihypertensive."},
{"text": "Isotretinoin", "explanation": "Isotretinoin is a highly potent teratogen (causing craniofacial, cardiac, and CNS defects) but is used for acne, not hypertension."},
{"text": "ACE Inhibitors (e.g., Lisinopril)", "explanation": "Correct. ACE inhibitors and ARBs are contraindicated in pregnancy (especially the 2nd and 3rd trimesters) as they are known teratogens (Type D ADR) that cause fetal renal failure and skull hypoplasia."},
{"text": "Warfarin", "explanation": "Warfarin is a teratogen (causing bone/cartilage defects), but the specific findings of renal failure and skull hypoplasia are classic for ACE inhibitors."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0021.jpg"
},
{
"id": 20,
"category": "Adverse Drug Reactions: Teratogenicity (PLLR)",
"questionText": "A physician is prescribing a new medication to a 28-year-old female of child-bearing potential. Instead of the old letter categories (A, B, C, D, X), the physician now consults the 'Pregnancy and Lactation Labeling Rule' (PLLR). What is the primary difference in this new labeling system?",
"options": [
{"text": "It uses a new, more detailed letter system (A+ through X-).", "explanation": "This is incorrect. The PLLR *removes* the letter category system entirely."},
{"text": "It provides a narrative summary under 'Pregnancy,' 'Lactation,' and 'Reproductive Potential.'", "explanation": "Correct. The PLLR replaces the overly simplistic letter categories with a detailed narrative summary of risks, clinical considerations, and data, organized into three subsections to improve clinical decision-making."},
{"text": "It only provides information on drugs that are 100% safe in pregnancy (Category A).", "explanation": "This is incorrect. The PLLR provides risk summaries for *all* drugs, removing the misleading Category A."},
{"text": "It is a pass/fail system based on animal studies only.", "explanation": "This is incorrect. The PLLR is a narrative summary that includes human data, animal data, and clinical considerations."},
{"text": "It states that all drugs are contraindicated in pregnancy until proven safe.", "explanation": "This is incorrect. The PLLR is a risk/benefit summary to *guide* prescribing, not a blanket contraindication."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0020.jpg"
},
{
"id": 21,
"category": "Adverse Drug Reactions: Definitions",
"questionText": "A patient is prescribed an antibiotic and is warned that a common 'side effect' is nausea. The patient takes the drug and experiences nausea, but no allergic reaction. How is this type of reaction, which is a known, non-deleterious effect of the drug at therapeutic doses, best classified?",
"options": [
{"text": "A Medication Error", "explanation": "A medication error is a *preventable* event in the prescribing or administration process; this is a pharmacologic effect of the drug itself."},
{"text": "An Idiosyncratic Reaction (Type B)", "explanation": "An idiosyncratic reaction is unpredictable and not dose-related (e.g., an allergy). Nausea from this antibiotic is a known, predictable effect."},
{"text": "A Side Effect (a type of Type A ADR)", "explanation": "Correct. A side effect is a predictable, dose-dependent (Type A) effect that is not the primary therapeutic goal and occurs at normal therapeutic doses."},
{"text": "A Toxic Reaction (a type of Type A ADR)", "explanation": "A toxic reaction is also Type A, but implies a *harmful* effect, often at *supratherapeutic* doses or due to accumulation (e.g., digoxin toxicity). Mild, expected nausea is a side effect."},
{"text": "A Delayed Reaction (Type D)", "explanation": "This is an immediate or acute effect of the dose, not a delayed effect like teratogenesis."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0011.jpg"
},
{
"id": 22,
"category": "Adverse Drug Reactions: Definitions",
"questionText": "A nurse misreads a physician's handwriting and administers 100 mg of a drug instead of the intended 10 mg. The patient suffers a toxic reaction. This event, which was preventable and resulted from an error in the medication use process, is best defined as:",
"options": [
{"text": "An Adverse Drug Reaction (ADR)", "explanation": "An ADR is harm *caused* by the drug at *normal* doses. This event is better defined as a medication error."},
{"text": "A Medication Error", "explanation": "Correct. A medication error is a preventable event in the medication use process (prescribing, transcribing, dispensing, administering) that may or may not lead to harm."},
{"text": "An Idiosyncratic Reaction (Type B)", "explanation": "This was a predictable toxic reaction to a massive overdose, not an unpredictable idiosyncratic reaction."},
{"text": "A Side Effect (Type A)", "explanation": "This was a toxic effect from an overdose, not a known, mild effect at a therapeutic dose."},
{"text": "A Delayed Reaction (Type D)", "explanation": "This was an acute toxic reaction, not a delayed one."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0077.jpg"
},
{
"id": 23,
"category": "Adverse Drug Reactions: Hypersensitivity (Type II)",
"questionText": "A patient taking methyldopa for hypertension develops anemia. A Coombs test is positive, and lab work confirms drug-induced hemolytic anemia, where antibodies (IgG and IgM) are directed against drug-coated red blood cells. This reaction is best classified as which type of hypersensitivity?",
"options": [
{"text": "Type I (Anaphylactic)", "explanation": "Type I is IgE-mediated and involves mast cell degranulation (e.g., anaphylaxis, urticaria)."},
{"text": "Type II (Cytotoxic)", "explanation": "Correct. Type II hypersensitivity is cytotoxic, where IgG or IgM antibodies bind to cell-surface antigens (here, the drug on the RBC), leading to cell destruction (hemolysis) via complement."},
{"text": "Type III (Immune Complex)", "explanation": "Type III involves antigen-antibody *complexes* depositing in tissues (e.g., serum sickness, vasculitis), not antibodies attacking cells directly."},
{"text": "Type IV (Cell-Mediated)", "explanation": "Type IV is a *delayed*, T-cell mediated reaction (e.g., contact dermatitis, SJS/TEN), not an antibody-mediated cytotoxic reaction."},
{"text": "Type F (Failure)", "explanation": "This is a classification for therapeutic failure, not an immunologic reaction."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0027.jpg"
},
{
"id": 24,
"category": "Adverse Drug Reactions: Hypersensitivity (Type III)",
"questionText": "A patient receives a non-human monoclonal antibody (e.g., from a mouse) for cancer treatment. Ten days later, he develops a fever, rash, arthralgias, and proteinuria. This is diagnosed as serum sickness. This reaction is caused by what immunologic mechanism?",
"options": [
{"text": "IgE-mediated mast cell degranulation.", "explanation": "This describes a Type I hypersensitivity reaction (anaphylaxis)."},
{"text": "IgG antibodies directed against the patient's own cell surfaces.", "explanation": "This describes a Type II (cytotoxic) hypersensitivity reaction."},
{"text": "Deposition of circulating antigen-antibody (IgG) complexes in tissues.", "explanation": "Correct. Serum sickness is a classic Type III hypersensitivity, where complexes of the foreign protein (antigen) and IgG (antibody) deposit in small vessels, joints, and glomeruli, activating complement and causing systemic inflammation."},
{"text": "T-cell mediated cytokine release and direct cell killing.", "explanation": "This describes a Type IV (cell-mediated) hypersensitivity reaction."},
{"text": "Direct, non-immunologic toxicity of the drug.", "explanation": "This would be a Type A (augmented) reaction; serum sickness is a Type B (immunologic) reaction."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0027.jpg"
},
{
"id": 25,
"category": "Adverse Drug Reactions: Hypersensitivity (Type IV)",
"questionText": "A patient uses a topical neomycin ointment on a skin abrasion. Two days later, the area becomes erythematous, pruritic, and indurated (contact dermatitis). This T-cell-mediated, delayed reaction is an example of which type of hypersensitivity?",
"options": [
{"text": "Type I (Anaphylactic)", "explanation": "Type I reactions are immediate (minutes) and IgE-mediated (e.g., hives), not delayed and T-cell mediated."},
{"text": "Type II (Cytotoxic)", "explanation": "Type II reactions are antibody-mediated against cells (e.g., hemolytic anemia)."},
{"text": "Type III (Immune Complex)", "explanation": "Type III reactions are caused by immune complex deposition (e.g., serum sickness)."},
{"text": "Type IV (Cell-Mediated)", "explanation": "Correct. Contact dermatitis is a classic Type IV (delayed-type) hypersensitivity, which is mediated by T-cells and occurs 24-72 hours after re-exposure to the antigen."},
{"text": "Type A (Augmented)", "explanation": "This is an unpredictable (Type B) immunologic reaction, not a predictable (Type A) pharmacologic effect."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0027.jpg"
},
{
"id": 26,
"category": "Pharmacogenomics: Warfarin",
"questionText": "A 67-year-old patient is being started on warfarin for atrial fibrillation. The physician orders genetic testing for CYP2C9 and VKORC1. What is the rationale for testing for *both* of these genes?",
"options": [
{"text": "CYP2C9 activates the prodrug, and VKORC1 metabolizes it.", "explanation": "This is incorrect. Warfarin is not a prodrug, and CYP2C9 metabolizes (inactivates) it."},
{"text": "Both genes code for transporters that excrete warfarin in the kidney.", "explanation": "This is incorrect. CYP2C9 is a metabolic enzyme, and VKORC1 is the drug's molecular target."},
{"text": "CYP2C9 metabolizes warfarin, and VKORC1 is the drug's molecular target.", "explanation": "Correct. Warfarin dosing is complex because genetic variants in CYP2C9 affect its *metabolism* (pharmacokinetics), while variants in VKORC1 (the target enzyme) affect the patient's *sensitivity* to the drug (pharmacodynamics)."},
{"text": "Both genes code for subunits of the CYP3A4 enzyme.", "explanation": "This is incorrect. They are two separate, unrelated genes that both happen to be crucial for warfarin's dose-response relationship."},
{"text": "CYP2C9 variants are linked to SJS, and VKORC1 variants are linked to myopathy.", "explanation": "These associations are incorrect; both variants relate directly to warfarin's anticoagulant effect and dosing."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0039.jpg"
},
{
"id": 27,
"category": "Drug Interactions: Pharmacodynamic",
"questionText": "A 70-year-old male with hypertension (treated with propranolol) and asthma (treated with albuterol) reports that his albuterol inhaler 'doesn't seem to work anymore.' This is a classic example of what type of drug interaction?",
"options": [
{"text": "Pharmacokinetic (PK) - CYP450 Induction", "explanation": "This is a pharmacodynamic interaction at the receptor level, not a metabolic (PK) one."},
{"text": "Pharmacokinetic (PK) - P-glycoprotein Inhibition", "explanation": "This is a pharmacodynamic interaction at the receptor level, not a transporter (PK) one."},
{"text": "Pharmacodynamic (PD) - Additive/Synergistic", "explanation": "This is an *antagonistic* interaction, as the two drugs have opposing effects."},
{"text": "Pharmacodynamic (PD) - Antagonistic", "explanation": "Correct. Propranolol (a non-selective beta-blocker) antagonizes the effect of albuterol (a beta-2 agonist) at the beta-2 receptors in the lungs, preventing bronchodilation."},
{"text": "Pharmacokinetic (PK) - Chelation", "explanation": "Chelation is a PK interaction that occurs during absorption in the GI tract."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 28,
"category": "Drug Interactions: Pharmacodynamic",
"questionText": "A 65-year-old patient on chronic warfarin therapy for atrial fibrillation is given aspirin for a headache. This combination puts the patient at a significantly increased risk of bleeding. This is what type of pharmacodynamic interaction?",
"options": [
{"text": "Antagonistic", "explanation": "This is incorrect. Both drugs *increase* bleeding risk, so their effects are synergistic/additive, not antagonistic."},
{"text": "Additive/Synergistic", "explanation": "Correct. This is a pharmacodynamic interaction where two drugs with different mechanisms (warfarin - anticoagulant; aspirin - antiplatelet) produce an exaggerated, additive/synergistic effect (bleeding)."},
{"text": "CYP450 Inhibition", "explanation": "While some NSAIDs *can* inhibit CYP2C9 (a PK interaction), the *primary* interaction between aspirin and warfarin is pharmacodynamic (anti-platelet + anti-coagulant)."},
{"text": "Plasma Protein Displacement", "explanation": "Aspirin can displace warfarin from albumin (a PK interaction), but the *additive effect* on hemostasis is the key pharmacodynamic interaction."},
{"text": "P-glycoprotein Induction", "explanation": "This is a pharmacokinetic interaction affecting absorption or excretion, not a pharmacodynamic one at the level of hemostasis."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0068.jpg"
},
{
"id": 29,
"category": "Drug Interactions: Pharmacodynamic",
"questionText": "A 25-year-old man at a party consumes a large amount of alcohol and then takes several diazepam (Valium) tablets. He is brought to the ED with profound CNS and respiratory depression. This life-threatening interaction is an example of:",
"options": [
{"text": "A Type B (Idiosyncratic) reaction", "explanation": "This is a predictable, dose-dependent, synergistic effect, not an unpredictable idiosyncratic reaction."},
{"text": "A Pharmacokinetic (CYP450) interaction", "explanation": "While acute alcohol can inhibit metabolism, the *primary* interaction is pharmacodynamic; both drugs are CNS depressants that act at the GABA-A receptor."},
{"text": "A Pharmacodynamic (Additive/Synergistic) interaction", "explanation": "Correct. Alcohol and benzodiazepines are both CNS depressants that enhance GABAergic neurotransmission, leading to a synergistic and life-threatening depression of the CNS and respiratory drive."},
{"text": "A Pharmacodynamic (Antagonistic) interaction", "explanation": "This is incorrect. The drugs have similar, not opposing, effects."},
{"text": "A Type D (Delayed) reaction", "explanation": "This is an acute toxicity, not a delayed reaction."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0068.jpg"
},
{
"id": 30,
"category": "Drug Interactions: Food (Grapefruit)",
"questionText": "A 58-year-old man on atorvastatin has recently started drinking a large glass of grapefruit juice every morning. He presents to his physician with severe muscle aches. This interaction is caused by grapefruit juice *inhibiting* which enzyme, leading to *increased* statin levels and toxicity?",
"options": [
{"text": "CYP2D6", "explanation": "CYP2D6 is inhibited by some drugs (like fluoxetine) but not grapefruit juice; it metabolizes codeine."},
{"text": "CYP2C19", "explanation": "CYP2C19 is inhibited by omeprazole, not grapefruit juice; it activates clopidogrel."},
{"text": "CYP3A4", "explanation": "Correct. Grapefruit juice is a potent inhibitor of intestinal CYP3A4. This decreases the first-pass metabolism of many drugs (like statins and calcium channel blockers), leading to markedly increased bioavailability and risk of toxicity (e.g., myopathy)."},
{"text": "P-glycoprotein (P-gp)", "explanation": "Grapefruit juice also inhibits P-gp, but its *CYP3A4* inhibition is the most clinically significant mechanism for this interaction."},
{"text": "VKORC1", "explanation": "This is the target of warfarin, not a metabolic enzyme inhibited by grapefruit juice."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0065.jpg"
},
{
"id": 31,
"category": "Drug Interactions: Food (Warfarin)",
"questionText": "A 70-year-old patient with a stable INR on warfarin suddenly develops a subtherapeutic INR (high risk of clotting) after changing his diet. The patient reports he 'started eating healthy' and now has a large spinach salad every day. What is the mechanism of this drug-food interaction?",
"options": [
{"text": "Pharmacokinetic - Spinach is a CYP2C9 *inducer*, increasing warfarin metabolism.", "explanation": "This is incorrect. The interaction is pharmacodynamic, not metabolic."},
{"text": "Pharmacokinetic - Spinach *inhibits* warfarin absorption.", "explanation": "This is incorrect. The interaction occurs after absorption at the site of action."},
{"text": "Pharmacodynamic - The high Vitamin K in spinach *antagonizes* the effect of warfarin.", "explanation": "Correct. Warfarin works by inhibiting VKORC1, which recycles Vitamin K. A large influx of dietary Vitamin K (from leafy greens) bypasses this blockade, antagonizing warfarin's effect and promoting clotting factor synthesis."},
{"text": "Pharmacodynamic - The high Vitamin K in spinach *potentiates* the effect of warfarin.", "explanation": "This is incorrect. Vitamin K *reverses* or *antagonizes* warfarin's effect, it does not potentiate it."},
{"text": "Pharmacokinetic - Spinach is a P-glycoprotein *inducer*, increasing warfarin excretion.", "explanation": "This is incorrect. The interaction is pharmacodynamic, not related to P-gp."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0039.jpg"
},
{
"id": 32,
"category": "Drug Interactions: Food (MAOI)",
"questionText": "A 45-year-old patient being treated for depression with phenelzine, a monoamine oxidase inhibitor (MAOI), attends a wine and cheese party. He consumes aged cheese and red wine, then develops a pounding headache, flushing, and a blood pressure of 220/130 mmHg. This hypertensive crisis is caused by what interaction?",
"options": [
{"text": "The alcohol in the wine synergistically depressed his CNS with the MAOI.", "explanation": "While this is a risk, the *hypertensive crisis* is due to tyramine."},
{"text": "The phenelzine inhibited CYP3A4, leading to toxic levels of the wine.", "explanation": "This is incorrect. The mechanism is pharmacodynamic, involving MAO and tyramine."},
{"text": "The tyramine in the cheese and wine, which is normally broken down by MAO, caused a massive release of norepinephrine.", "explanation": "Correct. MAOIs block the breakdown of tyramine in the gut and liver. Ingested tyramine (from aged/fermented foods) then enters the circulation and acts as an indirect sympathomimetic, displacing large amounts of norepinephrine from nerve terminals and causing a hypertensive crisis."},
{"text": "The patient is having a Type B (idiosyncratic) allergic reaction to the phenelzine.", "explanation": "This is a predictable (Type A) pharmacodynamic interaction in *any* patient taking an MAOI who consumes tyramine."},
{"text": "The phenelzine blocked sodium channels, leading to cardiac toxicity.", "explanation": "This describes the mechanism of other drug classes (e.g., TCAs), not the MAOI-tyramine interaction."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0065.jpg"
},
{
"id": 33,
"category": "Drug Interactions: PK (Absorption)",
"questionText": "A patient is prescribed ciprofloxacin for an infection. The physician instructs her to take the medication 'at least 2 hours before or 6 hours after' any dairy products or antacids containing calcium or magnesium. What is the reason for this instruction?",
"options": [
{"text": "These products inhibit CYP3A4, leading to ciprofloxacin toxicity.", "explanation": "This is incorrect. The interaction is not metabolic; it occurs in the GI tract before absorption."},
{"text": "These products induce CYP1A2, leading to therapeutic failure of the ciprofloxacin.", "explanation": "This is incorrect. The interaction is not metabolic."},
{"text": "These products alkalinize the stomach, which destroys the acid-labile ciprofloxacin.", "explanation": "This is incorrect. While pH can affect other drugs, the issue here is chelation."},
{"text": "The polyvalent cations (Ca<sup>2+</sup>, Mg<sup>2+</sup>) form an insoluble chelate with ciprofloxacin, preventing its absorption.", "explanation": "Correct. Fluoroquinolones and tetracyclines are known to chelate with polyvalent cations. This forms a large, insoluble complex in the gut, which cannot be absorbed and leads to therapeutic failure."},
{"text": "The ciprofloxacin will cause a hypertensive crisis if taken with these foods.", "explanation": "This describes the MAOI-tyramine interaction, not an antibiotic-calcium interaction."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0056.jpg"
},
{
"id": 34,
"category": "Drug Interactions: PK (Absorption)",
"questionText": "A patient with AIDS-related fungal esophagitis is prescribed ketoconazole, an antifungal that requires an acidic environment for dissolution. The patient is also taking omeprazole (a proton pump inhibitor) for GERD. The physician notes the fungal infection is not improving. What is the most likely mechanism for this therapeutic failure?",
"options": [
{"text": "Omeprazole is a CYP3A4 inducer, increasing the metabolism of ketoconazole.", "explanation": "Omeprazole is a CYP *inhibitor* (and substrate), but the primary interaction here is related to absorption, not metabolism."},
{"text": "Ketoconazole is a P-glycoprotein inhibitor, leading to its own toxic accumulation.", "explanation": "This describes a different PK interaction; the issue here is *lack* of effect, suggesting *low* levels."},
{"text": "The omeprazole-induced increase in gastric pH prevents the ketoconazole tablet from dissolving.", "explanation": "Correct. By suppressing gastric acid, the PPI (omeprazole) raises the gastric pH. This prevents the acid-dependent drug, ketoconazole, from dissolving properly, leading to poor absorption and therapeutic failure."},
{"text": "The two drugs form an insoluble chelate in the GI tract.", "explanation": "This describes interactions with polyvalent cations (e.g., calcium), not an interaction between a PPI and an azole antifungal."},
{"text": "Both drugs are competing for the same renal transporter, OAT.", "explanation": "This describes a renal excretion interaction (e.g., probenecid/penicillin), not this GI absorption interaction."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0068.jpg"
},
{
"id": 35,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A patient on a stable dose of simvastatin (metabolized by CYP3A4) begins taking St. John's Wort, an over-the-counter herbal supplement. Several weeks later, his physician notes his LDL cholesterol is no longer at goal. This therapeutic failure is due to St. John's Wort acting as a potent:",
"options": [
{"text": "Inhibitor of CYP3A4", "explanation": "An *inhibitor* (like grapefruit juice) would *increase* statin levels and risk of toxicity, not cause therapeutic failure."},
{"text": "Inducer of CYP3A4", "explanation": "Correct. St. John's Wort is a potent *inducer* of CYP3A4. This *increases* the first-pass metabolism of simvastatin, leading to *lower* plasma concentrations and therapeutic failure."},
{"text": "Inhibitor of P-glycoprotein", "explanation": "St. John's Wort is also a P-gp *inducer*, not an inhibitor."},
{"text": "Antagonist at the HMG-CoA reductase enzyme", "explanation": "This is incorrect. St. John's Wort is not a pharmacodynamic antagonist of statins; it is a pharmacokinetic inducer."},
{"text": "Chelating agent in the GI tract", "explanation": "This is incorrect. The interaction is metabolic, not one of absorption/chelation."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0063.jpg"
},
{
"id": 36,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A patient is taking clopidogrel (a prodrug activated by CYP2C19) after coronary stenting. Their physician now prescribes omeprazole (a potent CYP2C19 inhibitor) for GERD. This combination is dangerous because the omeprazole will:",
"options": [
{"text": "Increase the metabolism of clopidogrel, leading to bleeding.", "explanation": "Omeprazole is an *inhibitor*, it *decreases* metabolism. This would lead to *less* active drug, not more."},
{"text": "Decrease the metabolism of clopidogrel, leading to bleeding.", "explanation": "This is incorrect. While it *decreases* metabolism, this *prevents* the *activation* of the prodrug, leading to *therapeutic failure* (clotting), not bleeding."},
{"text": "Decrease the activation of the prodrug clopidogrel, leading to risk of thrombosis.", "explanation": "Correct. Omeprazole *inhibits* CYP2C19, the enzyme needed to *activate* the *prodrug* clopidogrel. This leads to subtherapeutic levels of the active anti-platelet metabolite and a high risk of stent thrombosis."},
{"text": "Increase the activation of the prodrug clopidogrel, leading to risk of thrombosis.", "explanation": "This is incorrect. An *inhibitor* *decreases* activation of a prodrug."},
{"text": "Displace clopidogrel from plasma proteins, leading to a transient risk of bleeding.", "explanation": "This is a metabolic (PK) interaction, not a protein displacement (PK) interaction. The outcome is clotting, not bleeding."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0064.jpg"
},
{
"id": 37,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A patient is prescribed carbamazepine, which is known to be a potent 'auto-inducer.' What does this mean for the patient's dosing regimen?",
"options": [
{"text": "The patient will need to start at a high dose and taper down as enzymes are inhibited.", "explanation": "This is incorrect. Carbamazepine is an *inducer*, not an inhibitor."},
{"text": "The patient must avoid all tyramine-containing foods.", "explanation": "This applies to MAOIs, not carbamazepine."},
{"text": "The patient will need to start at a low dose and titrate up as the drug induces its own metabolism.", "explanation": "Correct. 'Auto-induction' means carbamazepine *increases* the synthesis of the CYP enzymes that metabolize it. The dose must be started low and slowly titrated up over several weeks as the clearance of the drug gradually increases."},
{"text": "The drug will be 100% bioavailable and will not require dose adjustments.", "explanation": "This is incorrect. Auto-induction *requires* dose adjustments (titration) to maintain a therapeutic level."},
{"text": "The drug's half-life will get progressively *longer* over time.", "explanation": "Induction *increases* clearance, which will cause the half-life to get progressively *shorter* over the first few weeks."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0062.jpg"
},
{
"id": 38,
"category": "Drug Interactions: PK (Excretion)",
"questionText": "A patient is on a stable dose of digoxin. A physician adds quinidine for an arrhythmia. Shortly after, the patient develops signs of digoxin toxicity (nausea, vomiting, heart block). This interaction is caused by quinidine *inhibiting* which protein, thereby *decreasing* digoxin's clearance?",
"options": [
{"text": "CYP3A4", "explanation": "Digoxin is *not* primarily metabolized by CYP enzymes; it is cleared renally."},
{"text": "P-glycoprotein (P-gp)", "explanation": "Correct. Digoxin is a classic P-glycoprotein (P-gp) substrate and is actively pumped out by P-gp in the renal tubules. Quinidine is a potent P-gp *inhibitor*, which blocks this excretion, *decreasing* digoxin's clearance and leading to toxic accumulation."},
{"text": "VKORC1", "explanation": "This is the target of warfarin, not a transporter for digoxin."},
{"text": "Organic Anion Transporter (OAT)", "explanation": "OAT transports acidic drugs (like penicillin); digoxin is not a primary substrate."},
{"text": "SLCO1B1 (OATP1B1)", "explanation": "This is a hepatic *uptake* transporter associated with statins."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0069.jpg"
},
{
"id": 39,
"category": "Drug Interactions: PK (Excretion)",
"questionText": "A patient with gout is prescribed probenecid. This drug is known to increase the half-life of penicillin. What is the mechanism of this interaction in the renal tubule?",
"options": [
{"text": "Probenecid inhibits P-glycoprotein, reducing penicillin secretion.", "explanation": "Penicillin is transported by OAT, not P-glycoprotein."},
{"text": "Probenecid alkalinizes the urine, increasing penicillin reabsorption.", "explanation": "This describes pH trapping; the probenecid interaction is one of transporter competition."},
{"text": "Probenecid blocks the Organic Anion Transporter (OAT), reducing penicillin secretion.", "explanation": "Correct. Penicillin (a weak acid) is actively secreted into the tubule by OAT. Probenecid competes for and blocks this transporter, *decreasing* penicillin's renal clearance and *prolonging* its half-life."},
{"text": "Probenecid acidifies the urine, trapping the penicillin in the tubule.", "explanation": "Probenecid does not primarily work by acidifying the urine."},
{"text": "Probenecid induces CYP enzymes in the kidney, increasing penicillin reabsorption.", "explanation": "This is incorrect. The interaction is at the OAT transporter, not metabolic."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0060.jpg"
},
{
"id": 40,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A 55-year-old male on warfarin (metabolized by CYP2C9) for atrial fibrillation is given amiodarone for a ventricular arrhythmia. Amiodarone is a known, potent inhibitor of CYP2C9. What is the most likely consequence of adding amiodarone without adjusting the warfarin dose?",
"options": [
{"text": "Therapeutic failure of warfarin (subtherapeutic INR) and risk of stroke.", "explanation": "This would occur if amiodarone was an *inducer*. As an *inhibitor*, it will *increase* warfarin levels."},
{"text": "Marked increase in warfarin levels (supratherapeutic INR) and risk of severe bleeding.", "explanation": "Correct. Amiodarone *inhibits* the metabolism (clearance) of warfarin, causing it to accumulate. This leads to a dangerously high INR and a significant risk of life-threatening bleeding."},
{"text": "No interaction, as the two drugs are given for different cardiac conditions.", "explanation": "The *reason* for prescribing does not prevent a *pharmacokinetic* interaction from occurring."},
{"text": "A synergistic pharmacodynamic interaction at the level of the vitamin K receptor.", "explanation": "This is a *pharmacokinetic* (metabolic) interaction, not a pharmacodynamic one."},
{"text": "A rapid switch to zero-order kinetics for both drugs.", "explanation": "This is a first-order kinetics interaction (inhibition of metabolism), not a switch to zero-order."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0039.jpg"
},
{
"id": 41,
"category": "Drug Interactions: PK (Distribution)",
"questionText": "A patient on a stable dose of warfarin (99% protein-bound) is given valproic acid (also highly protein-bound) for seizures. The valproic acid displaces warfarin from its binding sites on plasma albumin. Which statement best describes the *immediate* effect and *long-term* outcome of this interaction?",
"options": [
{"text": "Immediate: Decreased free warfarin. Long-term: Decreased clearance.", "explanation": "Displacement *increases* the free fraction, which *increases* (not decreases) clearance."},
{"text": "Immediate: Increased free warfarin (risk of bleeding). Long-term: Increased clearance and a new steady state.", "explanation": "Correct. The *immediate* effect is a transient increase in the *free* (active) fraction, posing a bleeding risk. The *long-term* effect is that this higher free fraction is now available for metabolism, leading to *increased* clearance and a new (often similar) steady state."},
{"text": "Immediate: No change in free warfarin. Long-term: Decreased half-life.", "explanation": "There will be an immediate change in the free fraction, which is the clinical concern."},
{"text": "Immediate: Decreased free warfarin. Long-term: Therapeutic failure.", "explanation": "Displacement *increases* the free fraction, it does not decrease it."},
{"text": "Immediate: Increased free warfarin. Long-term: Increased half-life and permanent toxicity.", "explanation": "The increased free fraction leads to *increased clearance*, which *shortens* the half-life, not increases it. The toxicity risk is transient."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0038.jpg"
},
{
"id": 42,
"category": "Adverse Drug Reactions: Definitions",
"questionText": "A patient is prescribed a new blood pressure medication. The physician warns, 'This medication works by lowering your blood pressure, but if it lowers it too much, you may feel dizzy or lightheaded, especially when standing up.' This common, predictable, and dose-dependent adverse effect is best described as:",
"options": [
{"text": "An idiosyncratic reaction (Type B)", "explanation": "This is incorrect. This is a *predictable* pharmacologic effect, not an unpredictable, non-dose-related reaction."},
{"text": "A toxic effect (a type of Type A ADR)", "explanation": "Correct. This is a Type A (Augmented) reaction. It is a predictable, dose-dependent *toxic* effect, representing an exaggeration of the drug's primary therapeutic action (lowering blood pressure)."},
{"text": "A medication error", "explanation": "This is incorrect. The error is not in the prescribing or administration; it is a known pharmacologic property of the drug itself."},
{"text": "A Type IV hypersensitivity reaction", "explanation": "This is incorrect. This is a pharmacologic effect, not a delayed, T-cell-mediated immunologic reaction."},
{"text": "A Type F (Failure) reaction", "explanation": "This is incorrect. The drug is *working* (in fact, it's working too well), it is not *failing*."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0013.jpg"
},
{
"id": 43,
"category": "Adverse Drug Reactions: Definitions",
"questionText": "A patient begins taking an antibiotic for a sinus infection. The physician notes the antibiotic may disrupt normal gut flora, leading to C. difficile colitis. This type of adverse drug reaction, which is not the primary therapeutic effect but is a known consequence of the drug's mechanism, is best described as:",
"options": [
{"text": "A side effect (Type A)", "explanation": "A side effect is typically a minor, non-deleterious effect. C. difficile colitis is a severe, harmful effect."},
{"text": "A secondary effect (a type of Type A ADR)", "explanation": "Correct. This is a Type A (Augmented) reaction. A secondary effect is an indirect consequence of the drug's primary pharmacologic action (e.g., killing normal flora, leading to an opportunistic infection)."},
{"text": "An idiosyncratic reaction (Type B)", "explanation": "This is incorrect. Disruption of gut flora is a predictable pharmacologic effect of many broad-spectrum antibiotics, not an unpredictable, patient-specific reaction."},
{"text": "A Type III hypersensitivity reaction", "explanation": "This is incorrect. This is an indirect pharmacologic effect, not an immune-complex-mediated reaction."},
{"text": "A Type D (Delayed) reaction", "explanation": "This is incorrect. While it may take days to develop, it is not a 'delayed' reaction in the same sense as teratogenesis or carcinogenesis."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0011.jpg"
},
{
"id": 44,
"category": "Drug Toxicity: Antidotes (Opioids)",
"questionText": "A patient is brought in with classic signs of opioid overdose. The ED physician administers naloxone, and the patient's respiratory rate and consciousness immediately improve. This 'waking up' is an example of what type of pharmacodynamic interaction?",
"options": [
{"text": "Additive/Synergistic", "explanation": "This is incorrect. The drugs have opposing effects."},
{"text": "Antagonistic", "explanation": "Correct. Naloxone is a competitive antagonist that binds to the mu-opioid receptor with higher affinity than the opioid, displacing it and reversing its pharmacologic effect."},
{"text": "Pharmacokinetic (CYP450 Inhibition)", "explanation": "This is incorrect. Naloxone works directly at the receptor (pharmacodynamic), it does not change the metabolism of the opioid."},
{"text": "Pharmacokinetic (Protein Displacement)", "explanation": "This is incorrect. The interaction is pharmacodynamic, at the receptor."},
{"text": "Chemical Antagonism", "explanation": "Chemical antagonism involves one drug binding directly to another (e.g., chelation). Naloxone works at the *receptor*."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 45,
"category": "Drug Toxicity: Antidotes (Cocaine)",
"questionText": "A patient with cocaine-induced severe hypertension (220/130 mmHg) and tachycardia is given a benzodiazepine, which helps, but his BP remains dangerously high. Which of the following is the most appropriate *next* agent to manage his hypertension?",
"options": [
{"text": "Propranolol (a non-selective beta-blocker)", "explanation": "This is contraindicated. A beta-blocker would cause unopposed alpha-stimulation, worsening hypertension and coronary vasospasm."},
{"text": "Phentolamine (an alpha-blocker)", "explanation": "Correct. Cocaine toxicity is a state of massive alpha- and beta-adrenergic stimulation. After benzodiazepines, an alpha-blocker like phentolamine is used to reverse the severe vasoconstriction and hypertension."},
{"text": "Naloxone", "explanation": "This is the antidote for opioid overdose, not cocaine toxicity."},
{"text": "Atropine", "explanation": "Atropine is an anticholinergic used for bradycardia; this patient is tachycardic."},
{"textm": "Labetalol (a mixed alpha/beta-blocker)", "explanation": "While sometimes considered, a pure alpha-blocker like phentolamine is preferred to directly reverse the primary cause of the hypertension (vasoconstriction) without risking any unopposed alpha-activity."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0003.jpg"
},
{
"id": 46,
"category": "Drug Toxicity: Antidotes (Organophosphates)",
"questionText": "A farmer exposed to organophosphate pesticides is in a cholinergic crisis (bradycardia, profuse salivation, miosis). He is given atropine, which successfully dries his secretions and increases his heart rate. However, he remains profoundly weak and fasciculating. Why did atropine fail to reverse his muscle weakness?",
"options": [
{"text": "Atropine does not cross the blood-brain barrier.", "explanation": "While true for some anticholinergics, atropine *does* cross the BBB. The reason it fails is that it only works at *muscarinic* receptors."},
{"text": "Atropine only blocks muscarinic receptors, not nicotinic receptors.", "explanation": "Correct. Organophosphates inhibit AChE at *all* cholinergic synapses. Atropine only blocks the *muscarinic* effects (DUMBBELSS). The muscle weakness and fasciculations are *nicotinic* effects (at the neuromuscular junction), which require treatment with pralidoxime (2-PAM)."},
{"text": "The patient requires a benzodiazepine for organophosphate-induced seizures.", "explanation": "Benzodiazepines treat seizures but would not reverse the peripheral muscle weakness."},
{"text": "The patient's acetylcholinesterase is permanently inhibited.", "explanation": "This is true (aging), but it explains *why* the symptoms are occurring, not why atropine only treats *some* of them."},
{"text": "Atropine is an enzyme inducer and lowered its own plasma concentration.", "explanation": "This is incorrect. Atropine is a pharmacodynamic antagonist."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 47,
"category": "Drug Interactions: PK (General)",
"questionText": "A patient is taking Drug A, which is a substrate of P-glycoprotein (P-gp) and is also metabolized by CYP3A4. The patient begins taking rifampin, which is a potent *inducer* of both P-gp and CYP3A4. What will be the net effect on the oral bioavailability (F) and clearance (CL) of Drug A?",
"options": [
{"text": "F will increase and CL will increase.", "explanation": "F will *decrease* because induction of *both* intestinal P-gp (efflux) and CYP3A4 (first-pass metabolism) will reduce absorption."},
{"text": "F will decrease and CL will decrease.", "explanation": "CL will *increase* because induction of hepatic CYP3A4 and renal P-gp will increase systemic elimination."},
{"text": "F will increase and CL will decrease.", "explanation": "This is the opposite of the expected effect. This would be seen with an *inhibitor* of both pathways."},
{"text": "F will decrease and CL will increase.", "explanation": "Correct. Rifampin (an inducer) *increases* P-gp efflux and *increases* CYP3A4 metabolism. This results in *decreased* absorption/bioavailability (F) and *increased* systemic clearance (CL), leading to therapeutic failure."},
{"text": "F and CL will be unchanged as the two effects cancel each other out.", "explanation": "This is incorrect. Both induction effects are synergistic, leading to a profound *decrease* in drug levels."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0063.jpg"
},
{
"id": 48,
"category": "Drug Interactions: PK (General)",
"questionText": "A patient is taking Drug X, which is a substrate of P-glycoprotein (P-gp) and is also metabolized by CYP3A4. The patient starts drinking grapefruit juice daily, which is a potent *inhibitor* of both P-gp and CYP3A4. What is the most likely clinical outcome?",
"options": [
{"text": "Therapeutic failure due to decreased bioavailability.", "explanation": "This would be the effect of an *inducer* (like rifampin). Grapefruit juice is an *inhibitor*."},
{"text": "Increased risk of toxicity due to increased bioavailability.", "explanation": "Correct. Grapefruit juice (an inhibitor) *decreases* P-gp efflux and *decreases* CYP3A4 first-pass metabolism in the gut. This leads to a synergistic *increase* in oral bioavailability (F), causing higher-than-expected plasma levels and toxicity."},
{"text": "Therapeutic failure due to increased clearance.", "explanation": "Grapefruit juice *decreases* clearance (metabolism), it does not increase it."},
{"text": "Increased risk of toxicity due to decreased volume of distribution.", "explanation": "This interaction primarily affects *absorption* (F) and *clearance* (CL), not Vd."},
{"text." : "No effect, as grapefruit juice only affects CYP3A4, not P-glycoprotein.", "explanation": "Grapefruit juice is a known inhibitor of *both* intestinal CYP3A4 and P-glycoprotein."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0065.jpg"
},
{
"id": 49,
"category": "Pharmacogenomics: Warfarin",
"questionText": "A patient requires a much lower-than-average dose of warfarin to maintain a therapeutic INR. This patient's high sensitivity is most likely due to loss-of-function polymorphisms in which *two* genes?",
"options": [
{"text": "CYP2D6 and CYP2C19", "explanation": "These enzymes are involved in codeine and clopidogrel metabolism, respectively, not warfarin."},
{"text": "CYP2C9 and VKORC1", "explanation": "Correct. Loss-of-function variants in *CYP2C9* (the metabolic enzyme) *decrease* warfarin clearance. Variants in *VKORC1* (the target enzyme) *increase* sensitivity. Both variants necessitate a *lower* dose."},
{"text": "TPMT and NUDT15", "explanation": "These are involved in azathioprine metabolism."},
{"text": "G6PD and SLCO1B1", "explanation": "These are involved in hemolytic anemia and statin myopathy, respectively."},
{"text": "HLA-B*15:02 and HLA-B*57:01", "explanation": "These are HLA alleles associated with carbamazepine and abacavir hypersensitivity, respectively."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0039.jpg"
},
{
"id": 50,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A 50-year-old man who is a chronic heavy smoker requires a significantly higher-than-average dose of theophylline to manage his asthma. This is because components of tobacco smoke are potent *inducers* of which enzyme that metabolizes theophylline?",
"options": [
{"text": "CYP1A2", "explanation": "Correct. Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke are potent *inducers* of CYP1A2. Theophylline is a primary substrate of CYP1A2, so smokers have *increased* clearance and require *higher* doses."},
{"text": "CYP2C9", "explanation": "This enzyme metabolizes warfarin."},
{"text": "CYP2D6", "explanation": "This enzyme metabolizes codeine and many beta-blockers."},
{"text": "CYP3A4", "explanation": "While a major enzyme, it is not the primary one induced by smoking or the primary one that metabolizes theophylline."},
{"text": "CYP2C19", "explanation": "This enzyme activates clopidogrel."}
],
"correctAnswerIndex": 0,
"slideImagePath": "images/L117L118_p_page-0063.jpg"
},
{
"id": 51,
"category": "Drug Interactions: PK vs PD",
"questionText": "A patient taking warfarin (an anticoagulant) and ibuprofen (an NSAID) is at an increased risk of GI bleeding. Which statement accurately describes the *two* types of interactions occurring?",
"options": [
{"text": "PD: Ibuprofen is a P-gp inducer. PK: Both drugs are metabolized by CYP1A2.", "explanation": "This is incorrect. The interactions are CYP2C9 inhibition and the anti-platelet effect."},
{"text": "PD: Ibuprofen antagonizes the warfarin effect. PK: Ibuprofen chelates warfarin in the gut.", "explanation": "This is incorrect. The effects are additive/synergistic, not antagonistic."},
{"text": "PD: Additive anti-platelet effect of ibuprofen. PK: Ibuprofen inhibits CYP2C9 metabolism of warfarin.", "explanation": "Correct. This is a 'double whammy' interaction. Ibuprofen has its own *pharmacodynamic* anti-platelet effect (increasing bleed risk) AND it *pharmacokinetically* inhibits CYP2C9, reducing warfarin's clearance and increasing its concentration."},
{"text": "PD: Both drugs are vitamin K antagonists. PK: Both drugs are CYP3A4 inhibitors.", "explanation": "This is incorrect. Ibuprofen is an anti-platelet, not a vitamin K antagonist, and warfarin is a CYP2C9 substrate."},
{"text": "PD: Additive CNS depression. PK: Both drugs are renally cleared by OAT.", "explanation": "This is incorrect. Neither drug is a primary CNS depressant, and the interaction is not primarily renal."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0068.jpg"
},
{
"id": 52,
"category": "Adverse Drug Reactions: Definitions",
"questionText": "A patient begins taking an ACE inhibitor for hypertension. Within a week, they develop a persistent, dry, hacking cough, which is a known, non-deleterious effect of the drug's mechanism (bradykinin accumulation). This reaction is best classified as:",
"options": [
{"text": "A side effect (a type of Type A ADR)", "explanation": "Correct. A side effect is a predictable (Type A), dose-dependent, and non-deleterious effect that is not the primary therapeutic goal but is a known consequence of the drug's mechanism."},
{"text": "An idiosyncratic reaction (Type B)", "explanation": "This is incorrect. The ACE-inhibitor cough is a very common and predictable pharmacologic effect, not an unpredictable, patient-specific reaction."},
{"text": "A medication error", "explanation": "This is incorrect. This is a known pharmacologic property of the drug, not a preventable error in the medication process."},
{"text": "A Type II hypersensitivity reaction", "explanation": "This is incorrect. The cough is due to bradykinin, not an antibody-mediated cytotoxic reaction."},
{"text": "A Type D (Delayed) reaction", "explanation": "This is incorrect. This reaction occurs relatively soon after starting therapy, it is not a delayed effect like teratogenesis."}
],
"correctAnswerIndex": 0,
"slideImagePath": "images/L117L118_p_page-0011.jpg"
},
{
"id": 53,
"category": "Adverse Drug Reactions: Teratogenicity",
"questionText": "A 22-year-old female is prescribed isotretinoin for severe cystic acne. The physician requires her to use two forms of contraception and have monthly pregnancy tests as part of the iPLEDGE program. This stringent requirement is due to isotretinoin being a potent teratogen (Type D ADR) known to cause which pattern of defects?",
"options": [
{"text": "Phocomelia (limb deformities)", "explanation": "This is the classic defect associated with *thalidomide*."},
{"text": "Renal failure and skull hypoplasia", "explanation": "This pattern is classic for *ACE inhibitors*."},
{"text": "Craniofacial, cardiac, and central nervous system defects", "explanation": "Correct. Isotretinoin (a retinoid) is a highly potent teratogen known to cause severe craniofacial, cardiac, and CNS defects."},
{"text": "Hemolytic anemia", "explanation": "This is not a teratogenic effect, but a reaction seen in G6PD deficient individuals."},
{"text": "Hepatotoxicity and myelosuppression", "explanation": "These are toxicities, but not the specific teratogenic pattern of isotretinoin."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0021.jpg"
},
{
"id": 54,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "Which of the following describes the typical onset of action for a drug interaction caused by CYP450 *induction* versus one caused by CYP450 *inhibition*?",
"options": [
{"text": "Induction is rapid (hours), while inhibition is slow (weeks).", "explanation": "This is incorrect. Induction is slow, while inhibition is rapid."},
{"text": "Induction is slow (days to weeks), while inhibition is rapid (hours to days).", "explanation": "Correct. Induction requires the *synthesis of new enzyme proteins*, a slow process (days-weeks). Inhibition is a direct effect on existing enzymes and is therefore rapid (hours-days)."},
{"textm": "Both induction and inhibition are rapid (hours).", "explanation": "This is incorrect. Induction is a slow process."},
{"text": "Both induction and inhibition are slow (weeks).", "explanation": "This is incorrect. Inhibition is a rapid process."},
{"text": "The onset depends only on the half-life of the *substrate*, not the mechanism.", "explanation": "This is incorrect. The *mechanism* (induction vs. inhibition) is the primary determinant of the onset of the interaction."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0062.jpg"
},
{
"id": 55,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "Which of the following substances is a potent *inhibitor* of CYP3A4, known for causing significant drug interactions with statins and calcium channel blockers, leading to increased toxicity?",
"options": [
{"text": "Rifampin", "explanation": "Rifampin is a potent *inducer* of CYP3A4, which would *decrease* statin levels."},
{"text": "St. John's Wort", "explanation": "St. John's Wort is a potent *inducer* of CYP3A4."},
{"text": "Carbamazepine", "explanation": "Carbamazepine is a potent *inducer* of CYP3A4."},
{"text": "Grapefruit juice", "explanation": "Correct. Grapefruit juice is a classic, potent *inhibitor* of intestinal CYP3A4, which *decreases* the first-pass metabolism of substrates like statins and calcium channel blockers, *increasing* their bioavailability and risk of toxicity."},
{"text": "Tobacco smoke", "explanation": "Tobacco smoke is a potent *inducer* of *CYP1A2*, not an inhibitor of CYP3A4."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0065.jpg"
},
{
"id": 56,
"category": "Drug Interactions: PK (Metabolism)",
"questionText": "A patient is taking theophylline (metabolized by CYP1A2). Which of the following is a potent *inducer* of CYP1A2 that would *decrease* theophylline levels and lead to therapeutic failure?",
"options": [
{"text": "Ciprofloxacin", "explanation": "Ciprofloxacin is a potent *inhibitor* of CYP1A2, which would *increase* theophylline levels and cause toxicity."},
{"text": "Omeprazole", "explanation": "Omeprazole is an *inhibitor* of CYP2C19, not a relevant interactor with CYP1A2."},
{"text": "Grapefruit juice", "explanation": "Grapefruit juice is an *inhibitor* of CYP3A4."},
{"text": "Tobacco smoke", "explanation": "Correct. Polycyclic aromatic hydrocarbons (PAHs) in tobacco smoke are potent *inducers* of CYP1A2. This *increases* the clearance of theophylline, *lowering* its concentration and leading to therapeutic failure."},
{"text": "Ketoconazole", "explanation": "Ketoconazole is a potent *inhibitor* of CYP3A4."}
],
"correctAnswerIndex": 3,
"slideImagePath": "images/L117L118_p_page-0063.jpg"
},
{
"id": 57,
"category": "Adverse Drug Reactions: Hypersensitivity (Type III)",
"questionText": "A patient presents with a fever, urticaria, and joint pain one week after being treated with an anti-toxin derived from a horse. This reaction is characterized by the deposition of immune complexes in blood vessels. What is this classic Type III hypersensitivity reaction called?",
"options": [
{"text": "Anaphylaxis", "explanation": "Anaphylaxis is an immediate (Type I) IgE-mediated reaction."},
{"text": "Contact Dermatitis", "explanation": "Contact dermatitis is a delayed (Type IV) T-cell-mediated reaction."},
{"text": "Serum Sickness", "explanation": "Correct. Serum sickness is a classic Type III hypersensitivity caused by the formation and deposition of antigen-antibody (immune) complexes after exposure to a foreign protein, leading to systemic symptoms (fever, rash, arthralgia) 7-14 days later."},
{"text": "Drug-induced Hemolysis", "explanation": "This is a Type II (cytotoxic) reaction where antibodies attack blood cells directly."},
{"text": "Stevens-Johnson Syndrome (SJS)", "explanation": "SJS is a severe, delayed (Type IV) T-cell-mediated reaction."}
],
"correctAnswerIndex": 2,
"slideImagePath": "images/L117L118_p_page-0027.jpg"
},
{
"id": 58,
"category": "Drug Toxicity: Antidotes (Organophosphates)",
"questionText": "A patient with organophosphate poisoning is given pralidoxime (2-PAM). What is the specific molecular mechanism of this antidote?",
"options": [
{"text": "It competitively blocks muscarinic receptors to dry secretions.", "explanation": "This is the mechanism of *atropine*, which treats the *symptoms* but not the underlying cause."},
{"text": "It regenerates (reactivates) acetylcholinesterase by removing the phosphate group.", "explanation": "Correct. Pralidoxime (2-PAM) is a cholinesterase reactivator. It binds to the organophosphate and removes it from the enzyme, thereby *regenerating* AChE, but it must be given *before* 'aging' occurs."},
{"text": "It provides a source of glutathione to detoxify the poison.", "explanation": "This is the mechanism of *N-acetylcysteine* for acetaminophen poisoning."},
{"text": "It acts as a competitive antagonist at nicotinic receptors at the NMJ.", "explanation": "This is incorrect. 2-PAM *reverses* the inhibition of the *enzyme*, thereby *restoring* normal function at the nicotinic (and muscarinic) receptors."},
{"text": "It chelates the organophosphate in the blood, promoting renal excretion.", "explanation": "This is incorrect. It is an enzyme reactivator, not a chelator."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0059.jpg"
},
{
"id": 59,
"category": "Drug Interactions: PK (Absorption)",
"questionText": "A patient is taking an opioid for chronic pain, which slows GI motility. The patient is now prescribed a new medication in an extended-release (ER) formulation, which is absorbed throughout the small intestine. How might the opioid *increase* the absorption of the new ER drug?",
"options": [
{"text": "By increasing GI motility, causing the ER tablet to dissolve faster.", "explanation": "Opioids *decrease* GI motility, not increase it."},
{"text": "By decreasing GI motility, causing increased transit time and more complete absorption.", "explanation": "Correct. By slowing down GI motility, the opioid increases the 'transit time,' allowing the ER formulation to stay in the absorptive environment (small intestine) for longer, which can lead to *more complete* absorption than intended."},
{"text": "By inducing CYP3A4, which increases the first-pass effect.", "explanation": "Opioids are not primarily known as CYP inducers; the interaction is mechanical (motility)."},
{"text": "By inhibiting P-glycoprotein, which increases bioavailability.", "explanation": "This is incorrect. The primary interaction is mechanical (motility)."},
{"text": "By acidifying the stomach, which helps the ER tablet dissolve.", "explanation": "Opioids do not primarily work by acidifying the stomach."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0071.jpg"
},
{
"id": 60,
"category": "Drug Interactions: PK (Absorption)",
"questionText": "A patient is taking digoxin, a substrate of P-glycoprotein (P-gp). They are now prescribed rifampin, a potent *inducer* of P-gp. How will this interaction affect the oral bioavailability (F) of digoxin?",
"options": [
{"text": "F will increase, because rifampin inhibits the breakdown of digoxin.", "explanation": "Rifampin is an *inducer* of P-gp; it will *decrease* bioavailability, not increase it."},
{"text": "F will decrease, because rifampin increases P-gp efflux in the gut.", "explanation": "Correct. Rifampin *induces* (upregulates) P-glycoprotein, the efflux pump in the intestinal wall. This leads to *increased* pumping of digoxin *out* of the intestinal cells and back into the gut lumen, thereby *decreasing* its net absorption and bioavailability (F)."},
{"text": "F will be unchanged, as rifampin only affects CYP enzymes.", "explanation": "Rifampin is a classic inducer of *both* CYP enzymes and P-glycoprotein."},
{"text": "F will increase, because rifampin displaces digoxin from plasma proteins.", "explanation": "This describes a *distribution* interaction, not an *absorption* interaction, and the outcome would be complex, not a simple increase in F."},
{"text" : "F will decrease, because rifampin chelates digoxin in the stomach.", "explanation": "This is incorrect. The mechanism is induction of P-gp, not chelation."}
],
"correctAnswerIndex": 1,
"slideImagePath": "images/L117L118_p_page-0063.jpg"
}
];